From the Journals

Combo therapy does not improve outcomes for A. Baumannii



Adding meropenem to colistin had no effect on clinical success in cases of severe Acinetobacter baumannii infections, based on data from 406 patients.

The demographics were similar between the groups and approximately 77% of patients in each group were infected with A. baumannii.

A health care provider tends to a patient in a hospital bed. monkeybusinessimages/Thinkstock
The primary outcome was defined as clinical success 14 days after randomization; 79% (156) of the colistin-only patients and 73% (152) of the combination patients did not meet the criteria, the researchers said. In addition, no significant difference between the groups was noted in all-cause mortality at 14 days or 28 days, or for any other secondary outcomes including fever and time spent in the ICU.


Next Article:

   Comments ()